SLC5A2 and chronic kidney disease: Given the shared pathophysiology of CKD and HF, several treatment targets are common for both diseases (Figure 2), including the RAS, sodium‐glucose cotransporter 2 (SGLT2), MR and glucagon‐like peptide‐1 (GLP‐1) receptor.